MorphoSys AG — Earnings Release 2001

Aug 14, 2001

News Details

Ad-hoc | 14 August 2001 07:30

MorphoSys AG english

Ad hoc announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– MorphoSys Announces Second Quarter Results Quarter Marked by Record-level Revenues MorphoSys AG (Neuer Markt: MOR) today reported financial results for its second quarter and six months ended June 30, 2001. For the first six months of 2001, MorphoSys generated cumulative revenues of Euro 7.9 million, an increase of 172 percent over the same period of the previous year. In the second quarter Company revenues amounted to Euro 5.1 million, an amount surpassing all previously recorded quarterly revenue figures. Operating expenses for the first six months of 2001 increased to Euro 10.6 million from Euro 5.9 million in the year 2000. Cumulative Net Loss and Loss per Share for the first half-year of 2001 decreased by 15 percent compared to the same period in the prior year and amounted to Euro 2.2 million and Euro minus0.65, respectively, in 2001. Highlights of the second quarter included: – Expansion of the collaboration with ImmunoGen Inc. – Extension of the collaboration with Bayer for additional four years – Achievement of the second and final milestone with DuPont Pharmaceuticals – Dismissal of the Winter II patent infringement suit against MorphoSys in San Diego, California, and the filing for declaratory judgement at the District Court in Washington DC, seeking a confirmation that the Company does not infringe the Winter II patent end of ad hoc announcement (c) DGAP 14.08.2001 ——————————————————————————– WKN: 663200; Index: Nemax 50 Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 140730 Aug 01